EMA revises its conflict of interest policy; AbbVie all-oral HCV combo drug receives positive EU recommendation; Merck may help NewLink Genetics scale production of its Ebola vaccine.
In a company-hosted seminar today, the Paris-based drugmaker gave investors a preview of the future of its diabetes franchise.
The first approved hydrocodone formulated to discourage misuse raises a challenge to controversial Zohydro.
The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.
CRS asks if high prices are a tool to offset CMS rebates, the FDA adds another DTC study to its lineup, and the NIH proposes making more clinical trial data public.
With the purchase of Olson Communications, the agency aims to serve clients eager for expertise from outside the healthcare industry.
Success today is predicated on recognizing that every patient is different, every disease is different, every drug, every breakthrough and every cure is different.
Drug makers favor big spending on speakers' events and doctor outreach.
The scoop means the maker of HCV drugs Harvoni and Sovaldi can give any drug an accelerated review time.
Sanofi vets Takeda, devicemaker CEO candidates; Shaq returns for IcyHot; Royalty Pharma buys royalties on Vertex's Kalydeco.